News

In this issue, you'll find exciting news and original stories, a focus on our commitment on Epilepsy and our strategy to becoming a recognized Employer of Choice.

In 2020, billions of people faced a global pandemic for the first time in their lives, without having any experience or preparation for it. In this year everyone had to find new emotional, mental and physical resources. Angelini Pharma also wanted to do its part.

We are celebrating International Women's Day today, the annual opportunity to reflect on the progress achieved and call for greater gender equality changes.

Angelini Pharma never stops looking at future, with a foremost attention to innovative solutions and opportunities for identifying and enhancing promising health solutions.

On February 8th, the world celebrates International Epilepsy Day to raise awareness of one of the world's most prevalent neurological diseases.

Cenobamate has received a positive CHMP opinion for the adjunctive treatment of focal onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products.

For the second consecutive year, Angelini Pharma has obtained the Top Employers Europe 2021 certification.

Angelini Pharma announced today the acquisition of Arvelle Therapeutics, the Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system disorders.

Ovid Therapeutics yesterday announced the topline results from the Company’s Phase III NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.

In this issue, new stories and news, a focus on our commitment on mental health and our digital transformation, with the voices of the protagonists of our change.